Table 3

Characteristics of patient groups according to fulfilment of RA classification criteria at baseline and after follow-up

Characteristics of patient groups according to fulfilment of classification criteria at baselineCharacteristics of patient groups according to fulfilment of classification criteria after follow-up
1987 Criteria only; n=62010 Criteria only; n=46Both criteria; n=41Neither criteria; n=1121987 Criteria only; n=202010 Criteria only; n=16Both criteria; n=76Neither criteria; n=79
Age, years; median (IQR)65 (58–70)57 (45–67)60 (47–70)45 (32–63)62 (57–71)49 (43–55)60 (45–70)40 (29–55)
Female; n (%)4 (67)33 (72)20 (49)61 (54)10 (50)13 (81)43 (57)43 (54)
RF positive; n (%)0 (0)23 (50)26 (63)3 (3)0 (0)5 (31)44 (58)1 (1)
Anti-CCP positive; n (%)0 (0)23 (50)28 (68)1 (1)0 (0)3 (19)48 (63)0 (0)
Eventual outcome (after follow-up); n (%):
 Definitive non-RA diagnosis0 (0)4 (9)3 (7)7 (6)
 Self-limiting illness1 (17)12 (26)4 (10)61 (54)4 (20)11 (69)8 (11)53 (67)
DMARD use within first 18 months; n (%)
 Methotrexate4 (67)23 (50)27 (66)19 (17)12 (60)3 (19)48 (63)6 (8)
 Other1 (17)7 (15)8 (20)16 (14)2 (10)0 (0)16 (21)11 (14)
  • Anti-CCP, anticyclic citrullinated peptide antibody; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; RF, rheumatoid factor.